awareness

There is an outstanding need for new treatments for bladder cancer. We are proud to support the Bladder Cancer Advocacy Network in building awareness of the need for a cure.

results

Our preliminary Phase 3 data show Vicineumâ„¢ is well-tolerated and demonstrates efficacy in patients with high-grade NMIBC.

innovation

Vicineum is a targeted fusion protein designed to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates.

bringing new hope for treating bladder cancer

Vicineum is our novel, lead product candidate that we hope will change the treatment landscape for patients with high-grade, non-muscle invasive bladder cancer (NMIBC).

LEARN MORE
white-border-top

BLADDER CANCER

stat-ring

6th

most common cancer

stat-ring

72

average age of diagnosis

stat-ring

80,000+

new cases each year in the U.S.

stat-ring

$4 billion

annual costs

Top